Compare Novavax Inc (NVAX) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Okta, Inc. — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Okta, Inc. trades at $141.5 (market cap $25.79B). The key difference: Okta, Inc. is far larger — about 19.8× Novavax Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | OKTA | |
|---|---|---|
Market Cap | $1.30B | $25.79B |
Sector | Health | Technology |
52-Week High | $11.19 | $154.62 |
52-Week Low | $6.22 | $62.93 |
Enterprise Value | $800.50M | $23.62B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
